Enzymotec to Report First Quarter 2017 Financial Results
Get Alerts ENZY Hot Sheet
Join SI Premium – FREE
MIGDAL HA'EMEQ, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Wednesday, May 17, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, May 17, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #17202050 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/qhzwbm72, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit http://www.enzymotec.com.
Contact: The Ruth Group Tram Bui / Alexander Lobo (646) 536-7035 / 7037 [email protected] [email protected]Source: Enzymotec Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- First Bancorp to acquire First Carolina Bancshares for $166M
- Cantor Fitzgerald Reiterates Overweight Rating on Onto Innovation Inc. (ONTO) Ahead of Q2 Print
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share